74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Arbutus Biopharma Corp
Closed
3.41 -0.87
Overview
Share price change
24h
Min
3.41
Max
3.45
Income | 79K -20M |
|---|---|
Sales | -387K 1.3M |
EPS | -0.09 |
Profit margin | -1,472.517 |
Employees | 73 |
EBITDA | 54K -19M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +46.2 upside |
Next Earnings | 27 Feb 2025 |
|---|
Market Cap | 637M |
|---|---|
Previous open | 4.28 |
Previous close | 3.41 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Arbutus Biopharma Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Arbutus Biopharma Corp Forecast
Price Target
By TipRanks
46.2% upside
12 Months Forecast
Average 5 USD 46.2%
High 5 USD
Low 5 USD
Based on 2 Wall Street analysts offering 12 month price targets forArbutus Biopharma Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
